Loading...Loading...Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma company after it revealed significant progress with it weight-loss drug candidate.What Happened: Ark, through its ARK Genomic Revolution ETF ARKG, bought 11,360 shares of Amgen, Inc. AMGN, which rallied nearly 12% on Friday.

正在加载。。。正在加载。。。凯西·伍德·润方舟投资公司（CathieWoodRunArkInvest）于周五收购了一家生物制药公司的股票，此前该公司透露其减肥药候选药物取得了重大进展。发生了什么：方舟通过其方舟基因组革命ETF ARKG收购了安进公司AMGN的11360股，该股周五上涨近12%。

The purchase would have been worth $3.54 million.Following Friday’s purchase, Amgen’s weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund.See Also: Best ETFs To Buy Right NowWhy It’s Important: Amgen reported a double beat Thursday after the market close and offered an update on its obesity drug pipeline.

此次收购价值354万美元。在周五的收购之后，安进在ARKG的权重为1.06%，这归因于交易所交易基金持有的51712股。另请参见：目前最好买入的ETF为什么它很重要：安进在周四收盘后报告了双丰收，并提供了其肥胖药物管道的最新信息。

While pulling the plug on an early-stage oral obesity drug, codenamed “AMG 786,” the company said it was “differentially investing” in MariTide and a number of preclinical assets.MariTide, formerly AMG 133, is an injectable form of a drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1.

该公司在停止开发一种早期口服肥胖药物（代号为“AMG 786”）的同时，表示正在对马利肽和一些临床前资产进行“差异投资”。MariTide，以前称为AMG 133，是一种可注射形式的药物，靶向两种肠道激素-胃抑制多肽受体（GIP）和胰高血糖素样肽1（GLP-1）。

It is currently being evaluated in a Phase 2 obesity trial. “We're seeing a differentiated profile of MariTide and are confident that it will address important unmet medical needs, obesity, obesity-related conditions, and diabetes,” said Chief Scientific Officer Jay Bradner.The top-line 52-week data from the 11-arm Phase 2 study is on track for a readout in late 2024, the company said.The weight-loss drug market is estimated at a staggering $100 billion, with Novo Nordisk and Eli Lilly currently dominating the segment.ARKG closed Friday’s session up 3.51% at $25.04, according to Benzinga Pro data.Read Next: Cathie Wood’s Ark Goes Chip-Stock Shopping Ahead Of AMD Earnings, Adds More Of Warren Buffett-Backed Chinese EV PlayPhoto: ShutterstockLoading...Loading...Marke.

目前正在第二阶段肥胖试验中进行评估。首席科学官杰伊·布拉德纳（JayBradner）说：“我们看到马里蒂德（MariTide）的情况有所不同，相信它将解决重要的未满足的医疗需求、肥胖、肥胖相关疾病和糖尿病问题。”。该公司表示，来自11臂2期研究的52周数据有望在2024年末公布。减肥药市场估计高达1000亿美元，诺和诺德和礼来目前在该领域占据主导地位。根据Benzinga Pro数据，ARKG周五收盘上涨3.51%，至25.04美元。接下来阅读：凯西·伍德的方舟在AMD盈利之前购买芯片股，沃伦·巴菲特（WarrenBuffett）支持的中国电动汽车（EV）的更多内容补充道。